Anzeige
Mehr »
Mittwoch, 23.07.2025 - Börsentäglich über 12.000 News
Neubewertung voraus? Wird die Aktivierung der EU-Lizenz zum Kurs-Katalysator für die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40QEZ | ISIN: US59564R8079 | Ticker-Symbol: 5MP1
NASDAQ
23.07.25 | 19:14
0,900 US-Dollar
-0,56 % -0,005
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
BIODEXA PHARMACEUTICALS PLC ADR Chart 1 Jahr
5-Tage-Chart
BIODEXA PHARMACEUTICALS PLC ADR 5-Tage-Chart

Aktuelle News zur BIODEXA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.07.Biodexa Pharmaceuticals announces 1-for-10 reverse ADR split to regain Nasdaq compliance2
15.07.Biodexa Pharmaceuticals kündigt ADR-Ratio-Änderung im Verhältnis 1:10 an1
BIODEXA PHARMACEUTICALS Aktie jetzt für 0€ handeln
15.07.Biodexa Pharmaceuticals to implement 1:10 ADR ratio change1
15.07.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer1
15.07.Biodexa Pharmaceuticals PLC: ADR Ratio Change89July 15, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing...
► Artikel lesen
14.07.Biodexa files European clinical trial application for FAP treatment1
14.07.Biodexa Pharmaceuticals PLC: Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)193July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX)...
► Artikel lesen
27.06.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer-
27.06.Biodexa Pharmaceuticals PLC: Results of Annual General Meeting617June 27, 2023 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing...
► Artikel lesen
25.06.Biodexa Pharmaceuticals PLC: Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)160June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"),...
► Artikel lesen
23.06.Biodexa Pharmaceuticals PLC: Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)111June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX),...
► Artikel lesen
18.06.Biodexa enrolls first patient in type 1 diabetes drug trial4
18.06.Biodexa Pharmaceuticals: Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study1.492CARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition can be difficult. After all, with this type of diabetes, the body's immune...
► Artikel lesen
13.06.Biodexa Pharmaceuticals ändert Nennwert der Aktien3
11.06.Biodexa-Aktionäre stimmen allen Beschlüssen auf Hauptversammlung zu-
11.06.Biodexa Pharmaceuticals PLC: Result of General Meeting86June 11, 2025 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a...
► Artikel lesen
11.06.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer1
04.06.Biodexa Pharmaceuticals PLC: Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes160June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (Nasdaq: BDRX), a clinical stage...
► Artikel lesen
30.05.Biodexa Pharmaceuticals PLC: Shareholder Update503May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline...
► Artikel lesen
30.05.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer2
Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1